SCHEMBL34461950

SCHEMBL34461950

Fc1c(Cl)ncc2c(N3CCCC(F)(F)C3)ncnc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR2 O15552 2/20 0.41
GRIA1 P42261 1/20 0.37
LRRK2 Q5S007 3/20 0.37
ACACB O00763 1/20 0.36
GRM4 Q14833 2/20 0.35
SIGMAR1 Q99720 1/20 0.34
JAK3 P52333 4/20 0.33
MAPT P10636 2/20 0.33
JAK2 O60674 1/20 0.33
LCK P06239 1/20 0.33
LMNA P02545 1/20 0.33
PRNP P04156 1/20 0.33
ALOX15 P16050 1/20 0.33
TSHR P16473 1/20 0.33
PPARG P37231 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
NR2E3 Q9Y5X4 1/20 0.33
NCOR2 Q9Y618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30262655 0.84 CNR2 (0.40) FFAR2GRIA1GRM4SMN1; SMN2CNR2
SCHEMBL30600136 0.83 MAPT (0.48) SIGMAR1JAK3MAPTJAK2LMNA
SCHEMBL25078949 0.81 CNR2 (0.40) FFAR2GRIA1GRM4ALDH1A1SMN1; SMN2
SCHEMBL29235082 0.76 CNR2 (0.47) JAK2CNR2
SCHEMBL31460045 0.74 MEN1 (0.33) MAPTLMNAHTTNPSR1KDM4E
SCHEMBL29281579 0.74 KRAS (0.41)
SCHEMBL31113908 0.71 FFAR2 (0.42) FFAR2GRIA1LRRK2ACACBGRM4
SCHEMBL19724954 0.70 ACACB (0.44) FFAR2LRRK2ACACBSIGMAR1JAK3
SCHEMBL29235115 0.69 CNR2 (0.35) MAPTCHRM4SMN1; SMN2CNR2
SCHEMBL24535678 0.69 MAT2A (0.35) LRRK2ALDH1A1SMN1; SMN2CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12599672-B2 KRAS proteolysis targeting chimeras PAQ Therapeutics Inc. (US) 2026-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12599672-B2 KRAS proteolysis targeting chimeras KRAS, HRAS, NRAS FFAR2 4355/4885GRIA1 3837/4885LRRK2 722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.